News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
232,002 Results
Type
Article (5088)
Company Profile (24)
Press Release (226890)
Multimedia
Podcasts (2)
Webinars (4)
Section
Business (82244)
Career Advice (463)
Deals (15054)
Drug Delivery (8)
Drug Development (19073)
Employer Resources (30)
FDA (3682)
Job Trends (3909)
News (120176)
Policy (7512)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (293)
Accelerated approval (6)
Adcomms (4)
Allergies (14)
Alliances (14807)
ALS (38)
Alzheimer's disease (294)
Antibody-drug conjugate (ADC) (40)
Approvals (3782)
Artificial intelligence (80)
Autoimmune disease (27)
Automation (5)
Bankruptcy (97)
Best Places to Work (2865)
Biosimilars (32)
Biotechnology (23)
Bladder cancer (34)
Brain cancer (7)
Breast cancer (101)
Cancer (886)
Cardiovascular disease (61)
Career advice (395)
Career pathing (3)
CAR-T (64)
CDC (2)
Cell therapy (166)
Cervical cancer (5)
Clinical research (16682)
Collaboration (353)
Compensation (371)
Complete response letters (8)
COVID-19 (311)
CRISPR (13)
C-suite (338)
Cystic fibrosis (28)
Data (1325)
Denatured (1)
Depression (21)
Diabetes (78)
Diagnostics (2114)
Digital health (7)
Diversity (1)
Diversity, equity & inclusion (13)
Drug discovery (31)
Drug pricing (14)
Drug shortages (2)
Duchenne muscular dystrophy (35)
Earnings (42737)
Editorial (5)
Employer branding (6)
Employer resources (32)
Events (39134)
Executive appointments (424)
FDA (4420)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (340)
Gene editing (24)
Generative AI (5)
Gene therapy (102)
GLP-1 (144)
Government (422)
Guidances (197)
Healthcare (5045)
HIV (10)
Huntington's disease (5)
IgA nephropathy (11)
Immunology and inflammation (39)
Immuno-oncology (7)
Indications (16)
Infectious disease (337)
Inflammatory bowel disease (36)
Inflation Reduction Act (3)
Influenza (6)
Intellectual property (32)
Interviews (53)
IPO (7880)
IRA (3)
Job creations (1122)
Job search strategy (361)
JPM (4)
Kidney cancer (10)
Labor market (10)
Layoffs (106)
Leadership (5)
Legal (2337)
Liver cancer (21)
Longevity (2)
Lung cancer (92)
Lymphoma (70)
Machine learning (3)
Management (10)
Manufacturing (139)
MASH (50)
Medical device (3918)
Medtech (3928)
Mergers & acquisitions (7579)
Metabolic disorders (214)
Multiple sclerosis (18)
NASH (6)
Neurodegenerative disease (54)
Neuropsychiatric disorders (12)
Neuroscience (539)
NextGen: Class of 2026 (1674)
Non-profit (730)
Now hiring (5)
Obesity (84)
Opinion (32)
Ovarian cancer (26)
Pain (26)
Pancreatic cancer (38)
Parkinson's disease (50)
Partnered (6)
Patents (51)
Patient recruitment (96)
Peanut (6)
People (25216)
Pharmaceutical (7)
Pharmacy benefit managers (2)
Phase 1 (4994)
Phase 2 (7225)
Phase 3 (5788)
Pipeline (1962)
Policy (17)
Postmarket research (625)
Preclinical (1946)
Press Release (66)
Prostate cancer (57)
Psychedelics (3)
Radiopharmaceuticals (109)
Rare diseases (179)
Real estate (1886)
Recruiting (8)
Regulatory (5536)
Reports (17)
Research institute (308)
Resumes & cover letters (69)
Rett syndrome (19)
RNA editing (1)
RSV (2)
Schizophrenia (49)
Series A (53)
Series B (54)
Sickle cell disease (10)
Special edition (1)
Spinal muscular atrophy (33)
Sponsored (5)
Startups (1017)
Stomach cancer (1)
Supply chain (13)
Tariffs (7)
The Weekly (1)
Vaccines (80)
Venture capital (9)
Weight loss (29)
Women's health (6)
Date
Last 7 days (146)
Last 30 days (514)
Last 365 days (8884)
2026 (784)
2025 (9036)
2024 (11030)
2023 (13193)
2022 (18659)
2021 (19678)
2020 (18238)
2019 (13205)
2018 (10205)
2017 (10001)
2016 (9156)
2015 (12118)
2014 (9587)
2013 (7707)
2012 (8329)
2011 (8796)
2010 (8634)
Location
Africa (186)
Alabama (19)
Alaska (2)
Arizona (74)
Arkansas (1)
Asia (11782)
Australia (1690)
California (3541)
Canada (1138)
China (167)
Colorado (143)
Connecticut (162)
Delaware (70)
Europe (25486)
Florida (541)
Georgia (67)
Idaho (24)
Illinois (161)
India (14)
Indiana (105)
Iowa (9)
Japan (164)
Kansas (36)
Kentucky (17)
Louisiana (8)
Maine (51)
Maryland (352)
Massachusetts (2803)
Michigan (104)
Minnesota (201)
Mississippi (1)
Missouri (31)
Montana (17)
Nebraska (12)
Nevada (46)
New Hampshire (16)
New Jersey (1018)
New Mexico (5)
New York (814)
North Carolina (479)
North Dakota (4)
Northern California (1854)
Ohio (116)
Oklahoma (5)
Oregon (6)
Pennsylvania (597)
Puerto Rico (1)
Rhode Island (19)
South America (279)
South Carolina (17)
Southern California (1304)
Tennessee (61)
Texas (480)
United States (12328)
Utah (111)
Virginia (84)
Washington D.C. (17)
Washington State (297)
West Virginia (2)
Wisconsin (57)
Wyoming (1)
232,002 Results for "psychemedics corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Psychemedics Corporation Reports First Quarter 2024 Financial Results
Psychemedics Corporation, the world’s leading provider of hair testing for drugs of abuse, announced financial results for the first quarter ended March 31, 2024.
May 14, 2024
·
3 min read
Business
Psychemedics Corporation Reports 2023 Financial Results
Psychemedics Corporation, the world’s leading provider of hair testing for drugs of abuse, announced financial results for the year ended December 31, 2023.
March 28, 2024
·
4 min read
Business
Psychemedics Corporation Announces Relocation of Headquarters to Dallas, Texas
Psychemedics Corporation proudly announces the relocation of its corporate headquarters from Acton, Massachusetts, to Dallas, Texas, while reaffirming its unwavering dedication to delivering exceptional service and maintaining the highest standards in hair drug testing.
January 2, 2024
·
1 min read
Business
Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance
Psychemedics Corporation, a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice President - Finance.
November 27, 2023
·
1 min read
Press Releases
Psychemedics Corporation Reports Third Quarter 2024 Financial Results
November 13, 2024
·
1 min read
Business
Psychemedics Corporation Reports Third Quarter 2023 Financial Results
Psychemedics Corporation, a leading provider of hair testing for drugs of abuse, announced financial results for the third quarter ended September 30, 2023.
November 9, 2023
·
5 min read
Business
Psychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue Officer
Psychemedics Corporation, the world’s largest provider of hair testing for drugs of abuse, is pleased to announce the appointment of Shannon Shoemaker as its new Chief Revenue Officer.
September 21, 2023
·
2 min read
Genetown
Psychemedics Corporation Announces CEO Succession Plan
Psychemedics Corporation, the world’s largest provider of hair testing for drugs of abuse, announced that its board of directors has approved a transition plan for the Company’s President and CEO position.
July 12, 2023
·
3 min read
Business
Psychemedics Corporation Reports Second Quarter 2023 Financial Results
Psychemedics Corporation, the world’s largest provider of hair testing for drugs of abuse, announced financial results for the second quarter ended June 30, 2023.
August 11, 2023
·
6 min read
Genetown
Psychemedics Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 18, 2023
Psychemedics Corporation announced the grant of inducement awards to its newly appointed President and Chief Executive Officer, Brian Hullinger, upon his entering into employment with the Company in accordance with Nasdaq Listing Rule 5635.
August 18, 2023
·
1 min read
1 of 23,201
Next
